CN102452988B - 一种喹唑啉衍生物及其制备方法 - Google Patents

一种喹唑啉衍生物及其制备方法 Download PDF

Info

Publication number
CN102452988B
CN102452988B CN201010521382.4A CN201010521382A CN102452988B CN 102452988 B CN102452988 B CN 102452988B CN 201010521382 A CN201010521382 A CN 201010521382A CN 102452988 B CN102452988 B CN 102452988B
Authority
CN
China
Prior art keywords
intermediate product
formula
reaction
product
organic solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201010521382.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN102452988A (zh
Inventor
汪福意
罗群
纪丽云
郑伟
吕爽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Chemistry
Original Assignee
Institute of Chemistry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Chemistry filed Critical Institute of Chemistry
Priority to CN201010521382.4A priority Critical patent/CN102452988B/zh
Priority to EP11835642.7A priority patent/EP2634178B1/en
Priority to JP2013535272A priority patent/JP5837079B2/ja
Priority to US13/882,100 priority patent/US9233995B2/en
Priority to PCT/CN2011/081453 priority patent/WO2012055369A1/zh
Publication of CN102452988A publication Critical patent/CN102452988A/zh
Application granted granted Critical
Publication of CN102452988B publication Critical patent/CN102452988B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0046—Ruthenium compounds
    • C07F15/0053—Ruthenium compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0046—Ruthenium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F17/00—Metallocenes
    • C07F17/02—Metallocenes of metals of Groups 8, 9 or 10 of the Periodic Table

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CN201010521382.4A 2010-10-27 2010-10-27 一种喹唑啉衍生物及其制备方法 Expired - Fee Related CN102452988B (zh)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN201010521382.4A CN102452988B (zh) 2010-10-27 2010-10-27 一种喹唑啉衍生物及其制备方法
EP11835642.7A EP2634178B1 (en) 2010-10-27 2011-10-27 Quinazoline derivative and quinazoline complex protein kinase inhibitor for inhibiting multiplication of tumor cells and preparation method thereof
JP2013535272A JP5837079B2 (ja) 2010-10-27 2011-10-27 キナゾリン錯体、ならびにキナゾリン錯体の調製方法
US13/882,100 US9233995B2 (en) 2010-10-27 2011-10-27 Quinazoline derivatives and quinazoline complex protein kinase inhibitor for inhibiting multiplication of tumor cells and preparation method thereof
PCT/CN2011/081453 WO2012055369A1 (zh) 2010-10-27 2011-10-27 一种抑制肿瘤细胞增殖的喹唑啉衍生物、喹唑啉配合物蛋白激酶抑制剂及它们的制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201010521382.4A CN102452988B (zh) 2010-10-27 2010-10-27 一种喹唑啉衍生物及其制备方法

Publications (2)

Publication Number Publication Date
CN102452988A CN102452988A (zh) 2012-05-16
CN102452988B true CN102452988B (zh) 2016-01-27

Family

ID=45993179

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201010521382.4A Expired - Fee Related CN102452988B (zh) 2010-10-27 2010-10-27 一种喹唑啉衍生物及其制备方法

Country Status (5)

Country Link
US (1) US9233995B2 (enExample)
EP (1) EP2634178B1 (enExample)
JP (1) JP5837079B2 (enExample)
CN (1) CN102452988B (enExample)
WO (1) WO2012055369A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR092289A1 (es) 2011-11-14 2015-04-15 Sunshine Lake Pharma Co Ltd Derivados de aminoquinazolina y sus sales y metodos de uso
JP2017512776A (ja) * 2014-03-15 2017-05-25 ウェイク フォレスト ユニバーシティ 貴金属求電子体で修飾された官能化チロシンキナーゼ阻害剤およびそれと関連した方法
EP2924045A1 (en) * 2014-03-25 2015-09-30 Medizinische Universität Wien New agents for the treatment of cancer
CN106188147B (zh) * 2015-05-08 2021-08-20 中国科学院化学研究所 含喹唑啉类配体的Pt配合物及其制备方法和应用
CN105153047A (zh) * 2015-08-25 2015-12-16 佛山市赛维斯医药科技有限公司 含新型苯并喹唑啉和邻位氟结构的酪氨酸激酶抑制剂及用途
CN105153046A (zh) * 2015-08-25 2015-12-16 佛山市赛维斯医药科技有限公司 双卤素取代的乙氧基苯并喹唑啉类酪氨酸激酶抑制剂及用途
CN114524853B (zh) * 2022-02-28 2023-12-12 南京师范大学 一种全反式维甲酸-芳基金属配合物、制备方法及应用
CN116217550B (zh) * 2022-12-26 2024-12-27 上海前瞻创新研究院有限公司 一种咪唑三联吡啶钌配合物溶解氧检测探针及其制备方法与应用
CN119569738B (zh) * 2024-12-09 2026-05-08 太原学院 一种喹唑啉小分子化合物及其制备方法与应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068652A1 (en) * 2000-03-17 2001-09-20 Novo Nordisk A/S Condensed imidazoles as histamine h3 receptor ligands
WO2005097134A2 (en) * 2004-03-31 2005-10-20 The Scripps Research Institute Quinazoline based protein kinase inhibitors
CN1724521A (zh) * 2005-07-14 2006-01-25 沈阳中海生物技术开发有限公司 新的喹唑啉类衍生物、含有其的药物组合物以及它们的用途
CN1882567A (zh) * 2003-09-16 2006-12-20 阿斯利康(瑞典)有限公司 用作酪氨酸激酶抑制剂的喹唑啉衍生物
CN101367793A (zh) * 2008-09-26 2009-02-18 中国科学院广州生物医药与健康研究院 一种具有抗肿瘤活性的氨基喹唑啉衍生物及其盐类
US20090111772A1 (en) * 2007-09-10 2009-04-30 Xiong Cai Formulation of quinazoline based egfr inhibitors containing a zinc binding moiety
CN101431894A (zh) * 2006-01-17 2009-05-13 陈国庆 螺环化合物和应用方法
CN101535279A (zh) * 2006-09-11 2009-09-16 柯瑞斯公司 含锌结合基的喹唑啉基egfr抑制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ536114A (en) * 2002-03-30 2007-11-30 Boehringer Ingelheim Pharma 4-(N-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors
WO2005026150A1 (en) 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
US20100234371A1 (en) 2005-08-22 2010-09-16 Frank Himmelsbach Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof
ES2526718T3 (es) 2007-09-10 2015-01-14 Curis, Inc. Inhibidores de EGFR basados en sales de tartrato o complejos de quinazolina que contienen un resto que se une al cinc

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068652A1 (en) * 2000-03-17 2001-09-20 Novo Nordisk A/S Condensed imidazoles as histamine h3 receptor ligands
CN1882567A (zh) * 2003-09-16 2006-12-20 阿斯利康(瑞典)有限公司 用作酪氨酸激酶抑制剂的喹唑啉衍生物
WO2005097134A2 (en) * 2004-03-31 2005-10-20 The Scripps Research Institute Quinazoline based protein kinase inhibitors
CN1724521A (zh) * 2005-07-14 2006-01-25 沈阳中海生物技术开发有限公司 新的喹唑啉类衍生物、含有其的药物组合物以及它们的用途
CN101431894A (zh) * 2006-01-17 2009-05-13 陈国庆 螺环化合物和应用方法
CN101535279A (zh) * 2006-09-11 2009-09-16 柯瑞斯公司 含锌结合基的喹唑啉基egfr抑制剂
US20090111772A1 (en) * 2007-09-10 2009-04-30 Xiong Cai Formulation of quinazoline based egfr inhibitors containing a zinc binding moiety
CN101367793A (zh) * 2008-09-26 2009-02-18 中国科学院广州生物医药与健康研究院 一种具有抗肿瘤活性的氨基喹唑啉衍生物及其盐类

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Andrew J. Barker等.Studies leading to the identification of ZD1839 (IressaTM): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer.《Bioorganic & Medicinal Chemistry Letters》.2001,第11卷(第14期), *
Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy) -N-hydroxyheptanamide (CUDC-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer;Xiong Cai等;《Journal of Medicinal Chemistry》;20100209;第53卷(第5期);第2002页流程1和流程2，第2005页流程6 *
New trends for metal complexes with anticancer activity;Pieter CA Bruijnincx等;《Current Opinion in Chemical Biology》;20080125;第12卷(第2期);第197－206页 *
Studies leading to the identification of ZD1839 (IressaTM): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer;Andrew J. Barker等;《Bioorganic & Medicinal Chemistry Letters》;20010723;第11卷(第14期);第1912页流程2,第1913－1914页表1－3 *
新型8-氨基喹啉-蛋氨酸衍生物合钌金属药物的合成和细胞毒性及其与DNA相互作用研究;干宁等;《中国药学杂志》;20071008;第42卷(第19期);第1509页右栏图1 *

Also Published As

Publication number Publication date
US20130225811A1 (en) 2013-08-29
EP2634178A4 (en) 2013-09-04
EP2634178B1 (en) 2016-08-24
WO2012055369A1 (zh) 2012-05-03
EP2634178A1 (en) 2013-09-04
JP2013542210A (ja) 2013-11-21
JP5837079B2 (ja) 2015-12-24
US9233995B2 (en) 2016-01-12
CN102452988A (zh) 2012-05-16

Similar Documents

Publication Publication Date Title
CN102452988A (zh) 一种喹唑啉衍生物及其制备方法
KR101896599B1 (ko) 브로모도메인 억제제로서 유용한 테트라하이드로퀴놀린 유도체
CN101891627B (zh) 一种含有钌的配合物及其制备方法
CN101787025A (zh) 取代吴茱萸碱类抗肿瘤和抗真菌化合物及其制备方法
CN104341386A (zh) 一类芳基杂环小分子化合物、其衍生物及其制备方法和用途
CN109053592B (zh) 1-(2,5-二甲氧基苯基)-3-(取代嘧啶-4-基)脲类化合物及其制备和应用
CN108530365B (zh) 1,4-萘醌/蒽醌咪唑衍生物及其制备和用途
CN101289445A (zh) 苯胺喹唑啉衍生物、其制备方法及其用途
CN103922992B (zh) 一种抗癌活性吲哚酮衍生物、合成方法及其用途
CN104059062B (zh) 含苯并噻唑和三唑双杂环的稠环化合物及其应用
CN109053594B (zh) 1-(3,5-二甲氧基苯基)-3-(取代嘧啶-4-基)脲类化合物及其制备和应用
CN107163029A (zh) 一种改进的HSP90抑制剂Ganetespib的制备方法
CN108727377A (zh) 3-氰基吡唑并[1,5-a]嘧啶衍生物及其制备方法和用途
CN111777592A (zh) 一种n4-(2,5-二甲氧基苯基)-嘧啶二胺类靶向ddr1抑制剂及其制备和应用
CN103254191B (zh) 取代芳香四环类抗真菌化合物及其制备方法与应用
CN102850397B (zh) 多靶点抗肿瘤化合物及其制备方法和应用
CN106543194A (zh) 水仙环素衍生物及其制备与在制备抗肿瘤药物中的应用
CN118063485A (zh) 新型取代噻吩并嘧啶类化合物及其制备方法和应用
CN104586842A (zh) 一种抗癌活性吲哚衍生物、合成方法及其用途
CN116410203A (zh) 具有trk及其耐药突变抑制活性的化合物及其应用
CN114805375B (zh) 一种n-苯基烷氧基二苯并吖庚因类化合物、其制备方法及医药用途
CN102702116B (zh) 4-(3-氯-4-甲氧基苯胺基)-6-(3-胺基苯基)喹唑啉类化合物或其药学上可接受的盐和制备方法与应用
CN117247374B (zh) 一种bcl-xl抑制剂及其制药用途
CN113527304B (zh) 喹啉类TGF-β1抑制剂的制备方法
CN105085550B (zh) 一类alk激酶抑制剂及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160127